We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




HDPCR Technology-Based Non-Small-Cell Lung Cancer Assay to Expand Options for Faster, Targeted Treatment

By LabMedica International staff writers
Posted on 14 Jul 2023

Non-small-cell lung cancer (NSCLC) represents the majority of lung cancer cases. More...

Though targeted therapies have enhanced NSCLC survival rates recently, only around half of the patients receive timely biomarker testing for driver mutations to obtain targeted treatment. The barriers to this include expense, the absence of local testing facilities, a slow turnaround time for results, and the availability of insufficient or substandard tissue samples. Now, the early-access commercial launch of an NSCLC assay based on innovative High Definition PCR (HDPCR) technology could change all that.

ChromaCode, Inc. (Carlsbad, CA, USA) has launched a new HDPCR assay panel that can identify actionable NSCLC variations in nine significant genes using amplitude modulation and multi-spectral encoding. It requires only a small sample input and, thanks to simplified workflow and cloud-based analysis, can generate results in less than four hours. HDPCR technology offers a revolutionary approach, enabling deep multiplexing of actionable biomarkers in a single, rapid, and economical assay for multiple sample types on standard laboratory dPCR platforms. Its applications extend to oncology, organ transplant monitoring, and other genomics areas. ChromaCode Cloud complements HDPCR by offering quality insights and boosting lab performance. Utilizing proprietary signal processing data algorithms, this easy-to-use, cloud-based solution provides an integrated platform for seamless result analysis, secure data management, and streamlined reporting.

"The Early Access launch is a major milestone achievement for ChromaCode showcasing our oncology genomics platform; we are excited to announce the commercial availability of the NSCLC assay panel today" said Mark McDonough, Chief Executive Officer of ChromaCode. "The ChromaCode team is committed to positively impacting both the survival rates and the quality of life of the patients that we are privileged to serve. We endeavor to do this by providing our physician and laboratory partners with high quality, fast, lower cost solutions such as the ChromaCode HDPCR Non Small Cell Lung Cancer Assay to expand options for faster, targeted treatment."

Related Links:
ChromaCode, Inc


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.